Stocks · News reference
US stocks trade higher as Dow Jones gains over 350 points. Tech shares rise by 2% while consumer staples fall. 3M Co. sees 9% jump after strong earnings.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Bernstein Liebhard LLP announced an investigation into potential breaches of fiduciary duty by directors and officers of Calix, Inc. The law firm is seeking to determine whether company leadership fulfilled its obligations to shareholders. The investigation focuses on shareholders who purchased shares before January 28, 2026.
Bernstein Liebhard LLP has launched investigations into potential breaches of fiduciary duty by directors and officers at CarMax, Inc., Capricor Therapeutics, Inc., and Calix, Inc. The firm is seeking to determine whether company leadership acted in shareholders' best interests and is encouraging affected shareholders to contact them for legal consultation.
Bernstein Liebhard LLP announced an investigation into potential breaches of fiduciary duty by directors and officers of Gartner, Inc. The law firm is seeking to determine whether company leadership fulfilled its obligations to shareholders. The investigation targets shareholders who purchased shares before February 24, 2025.
Bernstein Liebhard LLP, an investor rights law firm, has announced investigations into potential breaches of fiduciary duty by directors and officers at AeroVironment, Capricor Therapeutics, and Calix. The firm is seeking to determine whether company leadership fulfilled obligations to shareholders and whether legal remedies may be available. Current shareholders are encouraged to contact the firm for consultation.
The global multiplex assays market is projected to grow from US$6.8 billion in 2025 to US$12.4 billion by 2030, at a 12.8% CAGR. North America leads with 34% market share, while Asia Pacific is the fastest-growing region at 15.5% CAGR. Consumables dominate with 68% market share, and protein multiplex assays hold 42%. Growth is driven by precision medicine, companion diagnostics, and laboratory automation.
The global lateral flow assay market is projected to grow from USD 10.84 billion in 2025 to USD 17.66 billion by 2035, with a 5.0% CAGR. Growth is driven by increased adoption of point-of-care testing, technological innovations including CRISPR-based assays, and the shift toward decentralized diagnostic models. Major players include Abbott, Roche, Siemens Healthineers, and Thermo Fisher Scientific, with infectious disease testing accounting for 72.2% of market share.